Apyx Medical Corp (APYX) Stock Price & Analysis
Apyx Medical Corp (APYX) rose 2.35% to USD 3.92 as of July 25, 2026 at 09:44 UTC, according to Nexqual real-time market data.
APYX last closed at USD 3.83; the session ranged USD 3.84–4.05 on volume of 51,723 shares. Market capitalization is $165.07M, with a 52-week range of USD 1.59–5.08 (NMS). Source: Nexqual, July 25, 2026 at 09:44 UTC.
Key Statistics (as of July 25, 2026 at 09:44 UTC)
| Price | USD 3.92 |
|---|---|
| Change | ▲ 2.35% (up) |
| Previous Close | USD 3.83 |
| Open | USD 3.9 |
| Day Range | USD 3.84 – 4.05 |
| 52-Week Range | USD 1.59 – 5.08 |
| Volume | 51,723 shares |
| Market Cap | $165.07M |
| Exchange | NMS |
Technical Analysis (APYX)
Nexqual's technical model rates APYX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.41 (neutral) |
| vs SMA50 | Below (USD 4.23) |
| MACD | -0.08 (negative) |
Analyst Ratings (APYX)
Wall Street analysts rate APYX "Strong Buy" based on 5 analysts, with a mean price target of USD 6.6 (range USD 6–8), per Nexqual as of July 25, 2026 at 09:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 6.6 |
| High Target | USD 8 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (APYX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $13.18M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.11 ▲ beat |
| 2025-12-31 | USD -0.03 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.05 vs est -0.1 ▲ beat |
| 2025-06-30 | USD -0.09 vs est -0.09 ▲ beat |
Source: Nexqual, July 25, 2026 at 09:44 UTC.
Financials & Fundamentals (APYX)
| Total Revenue | $55.90M |
|---|---|
| Revenue Growth (YoY) | +32.50% |
| Gross Margin | +63.15% |
| Operating Margin | -7.29% |
| Profit Margin | -16.40% |
| ROE | -76.49% |
| Debt / Equity | 301.51 |
| Current Ratio | 5.8 |
| Total Cash | $31.14M |
| Total Debt | $39.46M |
| Free Cash Flow | $-7.67M |
Source: Nexqual, July 25, 2026 at 09:44 UTC.
Financial Health Score (APYX)
Nexqual rates Apyx Medical Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:44 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 63%, operating -7% |
| Balance Sheet | Weak — $31M cash vs $39M debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -76%, ROA -4.4% |
Ownership (APYX)
| Insider Ownership | +13.61% |
|---|---|
| Institutional Ownership | +51.19% |
| Shares Outstanding | 42.11M |
| Float | 29.93M |
| Short % of Float | +0.64% |
Source: Nexqual, July 25, 2026 at 09:44 UTC.
Leadership (APYX)
Apyx Medical Corp is led by Charles D. Goodwin (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 09:44 UTC.
| President, CEO & Director | Charles D. Goodwin (age 58) |
|---|---|
| CFO, Treasurer & Secretary | Matthew C. Hill (age 56) |
| Chief Operating Officer | Shawn D. Roman (age 53) |
| Senior Vice President | Moshe Citronowicz (age 72) |
Major Backers & Investors (APYX)
Notable institutional backers of Apyx Medical Corp include Nantahala Capital Management, LLC, Archon Capital Management LLC, Royce & Associates LP, according to Nexqual as of July 25, 2026 at 09:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 8.21% |
| Archon Capital Management LLC | 6.66% |
| Royce & Associates LP | 6.23% |
| ROYCE FUND-Royce Small-Cap Opportunity Fund | 2.81% |
| AIGH Capital Management LLC | 2.64% |
| Silverberg Bernstein Capital Management LLC | 2.48% |
| Essex Investment Management Co LLC | 2.15% |
| ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc | 1.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.32% |
Source: Nexqual, July 25, 2026 at 09:44 UTC.
From Apyx Medical Corp's Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- We anticipate receiving clearance in the second quarter 2026.   Competition   Currently, we are the only company with helium-based plasma products and four specific indications from the FDA. With the launch of AYON, we now compete directly with companies that have devices that perform liposuction procedures.
- It also continues to be the subject of numerous presentations at traditional and cosmetic surgery conferences around the world.   This technology initially received FDA clearance in 2012 and a CE mark in December 2014, which enables us to sell our technology in the European Union.
- During 2021, we began to launch these new handpieces in our international markets, designed specifically for minimally invasive use, with improved ergonomics and safety features.   AYON Body Contouring System   AYON is an FDA-cleared device that provides the surgeon with an all-in-one system to perform any surgical procedure needed in their offices or surgical suite.
- We feel that our products and our strategy as a customer-centric aesthetic medical device manufacturer have, and will continue to improve, the lives of doctors and their patients.   Intellectual Property   We rely on our intellectual property that we have developed or acquired over the years including patents, trade secrets, technical innovations and various licensing agreements to provide our future growth and build our competitive position.
Partnerships
- In connection with the Asset Purchase Agreement with Symmetry Surgical in 2018, we entered into a Manufacturing and Supply Agreement for a ten-year term, pursuant to which we manufacture certain products and sell to them at agreed upon prices.
- The facility also distributes products directly to customers in certain international markets and provides warranty and repair services.   Joint Venture   In 2019, we executed a joint venture agreement with its Chinese supplier whereby we have a 51% ownership interest, to establish a presence in the Chinese market for the manufacturing and sale of our Surgical Aesthetics products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 0% |
| XGN | Exagen Inc. | USD 4.68 | ▼ 5.26% |
| AFIB | Acutus Medical Inc. | USD 0 | ▲ 0% |
| IDYA | IDEAYA Biosciences, Inc. | USD 35.4 | ▲ 1.14% |
| IRMD | iRadimed Corporation | USD 94.49 | ▲ 0.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:44 UTC. This page is informational and not investment advice.